Neovacs : Regulated information April 30, 2019

TOTAL NUMBER OF VOTING RIGHTS AND SHARES

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233- 8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority).

Date	Total number of shares	Number of existing	Number of existing
voting rights (GROSS)	voting rights (NET)
04/30/2019	121,642,366*	123,199,515	122,440,488

• including 2,026,315 new shares resulting from the conversion of "Ornane" through the agreement signed with European Select Growth Opportunities Fund and 990,000 new shares in favour of the employees

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by 4 patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

For more information on Neovacs, visit www.neovacs.fr

NEOVACS - Investor Relations

Charlène Masson

[phone] [e-mail]